Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study

Introduction. We report cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel observed in the phase III study CLEOPATRA in patients with HER2‐positive first‐line metastatic breast cancer (MBC). Patients and Methods. Left ventricular ejectio...

Full description

Saved in:

Bibliographic Details
Published in:	The oncologist (Dayton, Ohio) Vol. 18; no. 3; pp. 257 - 264
Main Authors:	Swain, Sandra M., Ewer, Michael S., Cortés, Javier, Amadori, Dino, Miles, David, Knott, Adam, Clark, Emma, Benyunes, Mark C., Ross, Graham, Baselga, José
Format:	Journal Article
Language:	English
Published:	Durham, NC, USA AlphaMed Press 01-03-2013
Subjects:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cardiac safety Double-Blind Method Female HER2 Humans LVSD Metastatic breast cancer Neoplasm Metastasis Pertuzumab Receptor, ErbB-2 - biosynthesis Stroke Volume - drug effects Taxoids - administration & dosage Taxoids - adverse effects Trastuzumab Ventricular Dysfunction, Left - chemically induced
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!